
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx is expected to experience strong growth in the US market as it continues to market and sell Barostim therapy to treat patients with heart failure with reduced ejection fraction (HFrEF). The company's improved sales strategy and focus on high-potential accounts are expected to drive further growth. The success of their product, BAROSTIM NEO, in combination with continued physician and patient marketing efforts, adequate reimbursement, and favorable clinical data, will also contribute to their growth. However, there are risks associated with limited long-term clinical data, reliance on third-party suppliers, and potential dilution. Management remains confident in their 2026 guidance and reiterated their projected revenue and margins for the year.
Bears say
CVRx is currently facing several challenges that may hinder its success in the future. These include its high reliance on the U.S. market for revenue, as well as its concentration on a single product, the BAROSTIM NEO, which has limited long-term clinical data on safety and efficacy. Additionally, CVRx's success is heavily dependent on its ability to demonstrate the benefits of BAROSTIM therapy to physicians and secure adequate reimbursement from government health authorities and insurers. The company also faces the risk of dilution due to its expectation of losses and potential need for future financing.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares